TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35496368
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg bolus completed 10 min before anesthesia induction followed by an infusion at 2.0 mg/kg/h)
Study: 35496368
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (volume-matched at the same infusion rate)
Study: 32105678
Drug: Valaciclovir (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir (8 g/d) given from the diagnosis of primary infection up to amniocentesis
Study: 32105678
Drug: Oral valaciclovir
Normalized name: valacyclovir Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valaciclovir (8 g/d) given to pregnant women with a mildly symptomatic fetus
Study: 32397821
Drug: Pika Pamoja
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pika Pamoja (treatment)
Study: 33269530
Drug: semaglutide 2.4
Normalized name: semaglutide 2.4 MG in 0.75 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: semaglutide 2.4 mg
Study: 36905345
Drug: semaglutide 1.7
Normalized name: semaglutide 1.7 MG in 0.75 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: semaglutide 1.7 mg
Study: 39514025
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tamoxifen
Study: 32081901
Drug: Dextromethorphan (NMDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (NMDA receptor antagonist)
Study: 33854132
Drug: Perampanel (AMPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (AMPA receptor antagonist)
Study: 33854132
Drug: Nimodipine (L-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (L-type voltage-gated calcium channel blocker)
Study: 32028996
Drug: Mass spectrometry
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass spectrometry identification of spots from the 2‐DE gel of D. hirsuta
Study: 33590901
Drug: Supportive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive treatment
Study: 34237668
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment and follow-up (Control)
Study: 35792064
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy (200 mg Q3W for up to 35 cycles + chemotherapy: paclitaxel 175 mg/m2 + cisplatin 50 mg/m2 or carboplatin AUC 5)
Study: 35792064
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (same chemotherapy regimen)
Study: 34343623
Drug: Preoperative lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative lateral quadratus lumborum block (40 mL, ropivacaine 0.25%)
Study: 34195765
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia with postoperative intravenous analgesia
Study: 32001384
Drug: Allograft bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allograft bone (30 g/level)
Study: 35315885
Drug: Prophylactic 40%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic 40% dextrose gel (n=681)
Study: 35315885
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (n=678)
Study: 35315885
Drug: Prophylactic 40%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic 40% dextrose gel
Study: 33053024
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus dexamethasone (20mg IV once daily for 5 days, then 10mg IV once daily for additional 5 days or until ICU discharge)
Study: 33053024
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without dexamethasone (Control Group)
Study: 36442498
Drug: Vi polysaccharide‐tetanus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi polysaccharide‐tetanus toxoid conjugate vaccine (Vi‐TT)
Study: 35598000
Drug: Structured educational
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured educational intervention based on the rational perception of postoperative pain and discomfort (anchoring and improved pain scale), and the proper use of analgesics
Study: 33723790
Drug: Synolis VA
Normalized name: VP/VA COPOLYMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synolis VA (80 mg hyaluronic acid and 160 mg sorbitol)
Study: 33723790
Drug: Synvisc-One (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synvisc-One (48 mg hylan GF-20)
Study: 33989539
Drug: Tri-antigenic hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-antigenic hepatitis B vaccine (TAV) - 10 μg, administered intramuscularly on days 0, 28, and 168.
Study: 33989539
Drug: Mono-antigenic hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mono-antigenic hepatitis B vaccine (MAV) - 20 μg, administered intramuscularly on days 0, 28, and 168.
Study: 33374575
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel containing diclofenac sodium, methyl salicylate, and lyophilized Calendula officinalis
Study: 34082075
Drug: Daily self-weighing
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-weighing (DSW) with instruction to weigh daily and provision of a web-enabled digital scale with graphical weight feedback
Study: 32718912
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg plus clopidogrel 75 mg daily
Study: 32718912
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg plus ticagrelor 90 mg twice daily
Study: 32738349
Drug: Methylene blue-assisted
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue-assisted photodynamic therapy (PDT) with FMPD
Study: 35475696
Drug: Automated insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated insulin delivery systems
Study: 34534923
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine 4 mg/kg via local infiltration at the end of spine surgery (age group 1)
Study: 34534923
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine 4 mg/kg via local infiltration at the end of spine or cardiac surgery (age group 2)
Study: 34534923
Drug: Bupivacaine hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine hydrochloride (HCl) 2 mg/kg via local infiltration at the end of spine surgery (age group 1)
Study: 33094466
Drug: Intravenous high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous high-dose vitamin C (3.0 g dissolved in 5% dextrose, 100 ml/time, 2 times/day)
Study: 33094466
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine therapy with intravenous drip of 5% dextrose and placebo, 100 ml/time, 2 times/day)
Study: 33094466
Drug: Intravenous high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous high-dose vitamin C
Study: 33124791
Drug: Statins (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (10 mg of rosuvastatin)
Study: 33602197
Drug: SRP using
Normalized name: SRP 299
DrugBank: SRP 299 (DB05440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP using EGCG solution as coolant
Study: 32333328
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg/Caffeine 100 mg FDC
Study: 35601970
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TMZ) administered in the morning (AM) before 10 am
Study: 35601970
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TMZ) administered in the evening (PM) after 8 pm
Study: 33920642
Drug: Nasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal steroid spray + BSE
Study: 33920642
Drug: Nasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal steroid spray + placebo tablet
Study: 33920642
Drug: Saline nasal
Normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline nasal spray + BSE
Study: 33920642
Drug: Saline nasal
Normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline nasal spray + placebo tablet
Study: 32406312
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium intake (3900 mg Na+/day)
Study: 33027800
Drug: Medical Nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Nutrition Therapy (MNT) for 12 weeks, involving 6 appointments with registered dietitians.
Study: 33027800
Drug: Medical Nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Nutrition Therapy (MNT) group
Study: 35705150
Drug: Fluid restriction
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid restriction (1500 mL/day)
Study: 36441736
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo (INP)
Study: 33714860
Drug: SOX (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOX (100 mg/m2 of oxaliplatin on day 1 and 80 mg/m2/day of S‐1 on days 1‐14, every 21 days, eight cycles)
Study: 33714860
Drug: UFT/LV (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT/LV (300 mg/m2 of UFT and 75 mg/day of LV on days 1‐28, every 35 days, five cycles)
Study: 32219623
Drug: MAKS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAKS treatment
Study: 35751307
Drug: Lidocaine hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine hydrochloride 2 mg/kg bolus dose
Study: 35751307
Drug: 0.9% normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline continuous intravenous infusion
Study: 32797700
Drug: Needle tip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle tip identification before injection
Study: 32797700
Drug: Failure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Failure to identify the needle tip before injection
Study: 34583659
Drug: Theory-based drug-use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theory-based drug-use prevention program (10 sessions of 45 minutes each)
Study: 34583659
Drug: Traditional didactic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional didactic teaching and drug refusal skill training
Study: 34583659
Drug: Theory-based drug-use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theory-based drug-use prevention program
Study: 32298326
Drug: 18-week exercise
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 18-week exercise intervention during chemotherapy
Study: 36805707
Drug: Inhaled prostacyclin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled prostacyclin
Study: 33228736
Drug: Corticosteroids (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (monthly intravenous methylprednisolone pulses or daily oral prednisolone)
Study: 33228736
Drug: Clobazam (oral)
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clobazam (oral)
Study: 35848625
Drug: Mobile application
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile application in addition to standard management (short counseling session and 1-month course of oral iron therapy)
Study: 35848625
Drug: Standard management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard management (short counseling session and 1-month course of oral iron therapy)
Study: 34236436
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g OBG (oat β-glucan) 3 times daily for 4 weeks
Study: 35235030
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection IS nerve block of 10 cc (133 mg) liposomal bupivacaine mixed with 10 cc of 0.5% bupivacaine (Group 1)
Study: 35235030
Drug: Continuous indwelling
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous indwelling IS nerve block catheter delivering 0.2% ropivacaine at a continual 4 cc/h infusion for the initial 3 post-operative days (Group 2)
Study: 35150880
Drug: Intravenous posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous posaconazole therapy followed by oral therapy (200 mg once daily after day 12)
Study: 35150880
Drug: Oral posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral posaconazole therapy (400 mg twice daily on day 1, followed by 400 mg once daily)
Study: 34293446
Drug: Clofazimine with
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofazimine with a median of 3 concomitant antibiotics
Study: 32525925
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy for 3 months
Study: 34933066
Drug: Twice-weekly hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly hemodialysis with adjuvant pharmacologic therapy for 6 weeks followed by thrice-weekly hemodialysis (incremental HD group)
Study: 34933066
Drug: Thrice-weekly hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly hemodialysis (conventional HD group)
Study: 34669886
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplementation (40 g daily for 15 days)
Study: 34669886
Drug: Casein supplementation
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein supplementation (40 g daily for 15 days)
Study: 33155296
Drug: OLS models
Normalized name: limonen-10-ol, (+)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLS models estimating SACE for periodontal treatment
Study: 32594760
Drug: Vasoactive intestinal
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive intestinal polypeptide (VIP) infusion
Study: 34495425
Drug: OMDI 0.002%
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMDI 0.002% once daily (Group 1 and Group 2)
Study: 34495425
Drug: OMDI 0.002%
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMDI 0.002% once daily + timolol 0.5% twice daily (Group 3)
Study: 34495425
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (timolol 0.5% twice daily)
Study: 32065601
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate prehydration (250 mL of 1.4% sodium bicarbonate administered in a 1-hour infusion)
Study: 35841512
Drug: Smartphone application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone application promoting preschooler's oral health
Study: 35841512
Drug: Common oral
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common oral health education (educational pamphlet and verbal explanations)
Study: 33421647
Drug: Propranolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (2 mg intravenous)
Study: 35921102
Drug: Active tDCS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tDCS group (30-minute daily sessions for 4 weeks, 2 mA anodal-right and cathodal-left prefrontal stimulation)
Study: 32006422
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (2.6 g/day)
Study: 32006422
Drug: Medium sodium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium sodium diet (6.0 g/day)
Study: 32006422
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium diet (18.0 g/day)
Study: 32382556
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (DEX)
Study: 34269813
Drug: Azithromycin (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1.2 g single oral dose)
Study: 34617558
Drug: MOS-supplemented infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOS-supplemented infant formula (7.2 g MOS/L)
Study: 32888340
Drug: Ziprasidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (10 mg)
Study: 32888340
Drug: Ziprasidone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (20 mg)
Study: 33650469
Drug: Golimumab concentration
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab concentration < 1.0 mg/L
Study: 33650469
Drug: Golimumab concentration
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab concentration 1.0–3.9 mg/L
Study: 33650469
Drug: Golimumab concentration
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab concentration ≥ 4.0 mg/L
Study: 33650469
Drug: Serum golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Serum golimumab concentration < 1.0 mg/L
Study: 33650469
Drug: Golimumab concentrations
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab concentrations ≥ 1.0 mg/L
Study: 32558624
Drug: Intragastric infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intragastric infusion of fructose (25g)
Study: 38939496
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg/d)
Study: 33016036
Drug: Protopine and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protopine and Nuciferine syrup, 10 ml, once a day, for 8 weeks
Study: 33016036
Drug: Placebo (flavoured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (flavoured coloured water), 10 ml, once a day, for 8 weeks
Study: 32842367
Drug: One shot
Normalized name: Acetaminophen 650 mg in 50 mL ORAL LIQUID [Headache Man No More Pills, One Shot, Headache Pain Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: One shot of carboplatin (76 mg/kg, i.p.)
Study: 32842367
Drug: Two shots
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two shots of carboplatin (76 mg/kg, i.p., one-week interval)
Study: 32755104
Drug: Alcohol dose
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol dose 0.06%
Study: 32755104
Drug: Alcohol dose
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol dose 0.08%
Study: 34322853
Drug: Prolonged-release fampridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release fampridine (PR-FAM) 10-mg tablet twice daily
Study: 32465771
Drug: IVIG +
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG + conventional antimicrobial therapy
Study: 32465771
Drug: Conventional antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antimicrobial therapy alone
Study: 32017092
Drug: Lactobacillus reuteri-containing
Normalized name: Lactobacillus reuteri-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri-containing lozenges (test group, n=36)
Study: 34460425
Drug: Lactulose:mannitol (L:M)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose:mannitol (L:M) test
Study: 33928883
Drug: Deutetrabenazine (fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine (fixed-dose 12-36 mg)
Study: 33928883
Drug: Deutetrabenazine (flexible-dose)
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deutetrabenazine (flexible-dose)
Study: 33387497
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy plus S-1
Study: 34622767
Drug: All biologic
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All biologic agents
Study: 33198070
Drug: Treatment modality
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment modality for RPI
Study: 36438075
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) plus low-dose aspirin treatment (Group A = 85)
Study: 36438075
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin treatment only (Group B = 88)
Study: 36438075
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) plus low-dose aspirin treatment (Group A)
Study: 34424549
Drug: Piroctone olamine
Normalized name: Piroctone Olamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroctone olamine (PO) containing leave-on treatment
Study: 32022904
Drug: Restrictive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive fluid therapy regimen
Study: 33186729
Drug: Intranasal Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal Fentanyl (INF)
Study: 33562001
Drug: Traditional slimming
Normalized name: arched swimming crab, cooked preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional slimming therapies using an individual diet plan and dietitian’s care
Study: 34357781
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg by mouth once daily and entinostat 5 mg by mouth once weekly (EE)
Study: 34357781
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg by mouth once daily and placebo 5 mg by mouth once weekly (EP)
Study: 34184336
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron preoperatively
Study: 34184336
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous iron (control group)